Galmed Pharmaceuticals Ltd
GLMD1.190USD
-0.145-10.85%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
6.31MMarket Cap
LossP/E TTM
More Details of Galmed Pharmaceuticals Ltd Company
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Galmed Pharmaceuticals Ltd Info
Ticker SymbolGLMD
Company nameGalmed Pharmaceuticals Ltd
IPO dateMar 13, 2014
CEOMr. Allen Baharaff
Number of employees3
Security typeOrdinary Share
Fiscal year-endMar 13
Address16 Tiomkin Street
CityTEL AVIV-YAFO
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code6578317
Phone97236938448
Websitehttps://www.galmedpharma.com
Ticker SymbolGLMD
IPO dateMar 13, 2014
CEOMr. Allen Baharaff
Company Executives of Galmed Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baharaff (Allen)
0.67%
Morgan Stanley & Co. LLC
0.61%
Schonfeld Strategic Advisors LLC
0.42%
Cambridge Investment Research Advisors, Inc.
0.18%
UBS Financial Services, Inc.
0.13%
Other
97.98%
Shareholders
Shareholders
Proportion
Baharaff (Allen)
0.67%
Morgan Stanley & Co. LLC
0.61%
Schonfeld Strategic Advisors LLC
0.42%
Cambridge Investment Research Advisors, Inc.
0.18%
UBS Financial Services, Inc.
0.13%
Other
97.98%
Shareholder Types
Shareholders
Proportion
Individual Investor
1.19%
Research Firm
0.65%
Hedge Fund
0.42%
Investment Advisor
0.34%
Other
97.39%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
29
77.68K
1.42%
-11.92K
2025Q2
36
135.24K
2.48%
+20.85K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
2023Q2
57
33.03K
13.93%
-6.52K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baharaff (Allen)
36.94K
0.67%
+8.83K
+31.44%
Mar 21, 2025
Morgan Stanley & Co. LLC
33.48K
0.61%
+33.48K
--
Jun 30, 2025
Schonfeld Strategic Advisors LLC
23.19K
0.42%
-2.00K
-7.94%
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
10.13K
0.18%
+10.13K
--
Jun 30, 2025
UBS Financial Services, Inc.
6.90K
0.13%
+5.80K
+525.27%
Jun 30, 2025
Nehemya (Guy)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.11%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.06%
+3.12K
+1148.16%
Mar 21, 2025
Sidransky (David)
3.12K
0.06%
+3.08K
+7338.10%
Mar 21, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
Date
Type
Ratio
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
